Amgen’s Parsabiv receives EC approval in secondary hyperparathyroidism
Amgen Inc., a leading American biopharmaceutical company, has achieved a significant milestone with the approval of its drug Parsabiv (etelcalcetide) by the European Commission (EC) for the treatment of secondary hyperparathyroidism (sHPT) in adult patients undergoing hemodialysis due to chronic renal disease. Breakthrough in sHPT Management sHPT is a complex and chronic condition that affects […]